TheraMind: a multi-LLM ensemble for accelerating drug repurposing in lung cancer via case report mining.

Published clinical case reports are a valuable yet underutilized source of evidence for drug repurposing. However, systematically identifying relevant reports remains a challenge due to the volume of literature and the diversity of candidate compounds. We present TheraMind, an AI system that leverages large language models (LLMs) to automate the identification and analysis of case reports supporting potential drug repurposing for non-small cell lung cancer (NSCLC). Our system screened 10,023 PubMed-indexed case reports across 18 candidate drugs using coordinated data extraction and standardized four-question prompts assessing diagnosis, drug administration, discontinuation, and clinical outcomes. We employed three evaluation strategies, rule-based classifiers, single-model validators, and a majority-vote ensemble integrating GPT-40-mini, Gemini-2.0-Flash, and LLaMA-3-8B. The ensemble approach achieved 92% recall and 99.7% specificity in detecting clinically relevant reports. Structured outputs included patient demographics, therapeutic responses, and case summaries. This LLM-driven framework offers a scalable approach to accelerate drug repurposing by mining real-world evidence from unstructured clinical literature.